Preclinical studies of RUC-4, a novel platelet αIIbβ3 antagonist, in non-human primates and with human platelets

INTRODUCTION: We are developing the novel αIIbβ3 antagonist, RUC-4, for subcutaneously (SC)-administered first-point-of-medical-contact treatment for ST segment elevation myocardial infarction (STEMI). METHODS: We studied the (1) pharmacokinetics (PK) of RUC-4 at 1.0, 1.93, and 3.86 mg/kg intravenou...

Descripción completa

Detalles Bibliográficos
Autores principales: Vootukuri, Spandana, Li, Jihong, Nedelman, Mark, Thomas, Craig, Jiang, Jiang-Kang, Babayeva, Mariana, Coller, Barry S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753935/
https://www.ncbi.nlm.nih.gov/pubmed/31544007
http://dx.doi.org/10.1017/cts.2019.382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753935/
https://www.ncbi.nlm.nih.gov/pubmed/31544007
http://dx.doi.org/10.1017/cts.2019.382

Ejemplares similares